摘要
目的 为应用证据图谱系统,对慢性阻塞性肺疾病干预的中医药相关研究证据进行鉴别、描述和评价。方法 于2023年11月前在CNKI、万方、VIP、SinoMed、PubMed、Web of Science以及Cochrane Library等数据库检索,进行系统评价/Meta分析/网状Meta分析,使用AMSTAR 2量表对纳入研究进行质量评估。结果 最终纳入111篇系统评价/Meta分析/网状Meta分析。观察组多数为中药汤剂治疗,治疗方法多为温补、消通、清解等。中医药治疗慢性阻塞性肺疾病可以增加肺功能和6 min步行距离(6-minute walking distance,6WMD),提高有效率和动脉血氧分压(Arterial oxygen partial pressure,PaO_(2)),缓解临床症状,提高患者的生活质量。根据AMSTAR 2量表评价结果显示,系统评价/Meta分析整体方法学质量不高,缺乏足够的证据支撑中医治疗的疗效。结论 中医药治疗慢性阻塞性肺疾病有一定疗效,但是纳入文献的证据质量有待提高,今后应开展高质量研究以提供循证依据。
Objective To apply the evidence mapping system,the evidence of traditional Chinese medicine related research on chronic obstructive pulmonary disease intervention was identified,described and evaluated.Methods CNKI,Wanfang,VIP,SinoMed,PubMed,Web of Science,Cochrane Library and other databases were searched before November 2023 to obtain systematic review/meta-analysis/network meta-analysis.The AMSTAR 2 scale was used to evaluate the quality of the included studies.Results A total of 111 systematic reviews/Meta-analysis/network Metaanalysis were included.In the observation group,most of them were treated with traditional Chinese medicine decoction,and the treatment methods were mostly warming,eliminating,clearing and so on.Traditional Chinese medicine treatment of chronic obstructive pulmonary disease could increase lung function and 6-minute walking distance(6WMD),improve efficiency and arterial oxygen partial pressure(PaO2),relieve clinical symptoms and improve the quality of life of patients.According to the evaluation results of AMSTAR 2 scale,the overall methodological quality of systematic review/Meta-analysis was not high,and there was a lack of sufficient evidence to support the efficacy of TCM treatment.Conclusion Traditional Chinese medicine has a certain effect on the treatment of chronic obstructive pulmonary disease,but the quality of evidence included in the literature needs to be improved.In the future,high-quality research should be carried out to provide evidence-based evidence.
作者
王星元
臧凝子
庞立健
吕晓东
WANG Xingyuan;ZANG Ningzi;PANG Lijian;LYU Xiaodong(First Clinical College of Liaoning University of Traditional Chinese Medicine,Shenyang 110847,China;Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110032,China)
出处
《世界科学技术-中医药现代化》
北大核心
2025年第3期842-855,共14页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
中国博士后科学基金项目(2022MD723797):基于HIF-1α/BNIP3L信号补肺健脾通络法抑制线粒体自噬改善COPD合并骨骼肌功能障碍机制研究,负责人:臧凝子
2023辽宁省科技计划联合计划应用基础研究项目(2023021095-JH2/1017):中药复方清络饮下调TLR9/NF-κB/IL-6通路干扰中性粒细胞胞外陷阱抑制EMT干预AE-IPF疗效机制研究,负责人:臧凝子
中医藏象理论及应用教育部重点实验室开放基金(zyzx2210):参苓补肺通络汤下调HIF-1α信号抑制线粒体自噬改善COPD合并骨骼肌功能障碍机制研究,负责人:臧凝子。
